Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: Comparative safety profiles of newer agents

Kevin Kelly, Ronan Swords, Devalingam Mahalingam, Francis J. Giles

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML). Although long-term safety and efficacy have been established, some patients will not respond to imatinib. Nilotinib and dasatinib successfully recapture responses for most patients with imatinib-refractory or -intolerant disease. These drugs have different safety profiles, which are likely associated with their divergent inhibitory targets. The presence of BcrAbl mutations and safety profiles of available therapies in relation to patient history should be considered when choosing a second-line agent. This review evaluates the safety and tolerability of agents approved for CML treatment and briefly discusses newer third-line agents.

Original languageEnglish (US)
Pages (from-to)1399-1413
Number of pages15
JournalLeukemia and Lymphoma
Volume51
Issue number8
DOIs
StatePublished - Aug 1 2010

Keywords

  • chronic myeloid leukemia
  • dasatinib
  • Imatinib
  • nilotinib
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: Comparative safety profiles of newer agents'. Together they form a unique fingerprint.

  • Cite this